Amitriptyline - CAS 50-48-6
Catalog number:
B0084-069863
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H23N
Molecular Weight:
277.41
COA:
Inquire
Description:
Amitriptyline is a derivative of dibenzocycloheptadiene and in the tricyclic antidepressant (TCA) class. It is a medicine used to treat a number of mental illnesses, including major depressive disorder and anxiety disorder. It is also used for prevention of migraines and treatment of neuropathic pain such as fibromyalgia and postherpetic neuralgia. It appears to prevent the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. It also inhibits cholinergic and alpha-1 adrenergic responses to bioactive amines. It was developed by AstraZeneca. It has been withdrawn from the market.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-069863 10 g $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
derivative of dibenzocycloheptadiene, mental illnesses
Purity:
95%
Appearance:
Solid powder
Synonyms:
3-(10,11-Dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n,n-dimethyl-1-propanamine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-; 3-(5,6-Dihyd
Solubility:
H2O:9.7 mg/mL
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Amitriptyline is a medicine used to treat a number of mental illnesses, including major depressive disorder and anxiety disorder. It is also used for prevention of migraines and treatment of neuropathic pain such as fibromyalgia and postherpetic neuralgia
Quantity:
Grams to Kilograms
Boiling Point:
195-205 °C
Melting Point:
196.5 °C
Density:
1.076±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
KRMDCWKBEZIMAB-UHFFFAOYSA-N
InChI:
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
Canonical SMILES:
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
Current Developer:
Amitriptyline was developed by AstraZeneca. It has been withdrawn from the market.
1.Impact of combined treatment with rosuvastatin and antidepressants on liver and kidney function in rats.
Herbet M1, Gawrońska-Grzywacz M1, Izdebska M1, Piątkowska-Chmiel I1, Jagiełło-Wójtowicz E1. Exp Ther Med. 2016 Apr;11(4):1459-1464. Epub 2016 Feb 10.
Depression is among the most prevalent and life-threatening forms of mental illness, and is also a risk factor for cardiovascular disorders, diabetes and metabolic syndrome. Elderly patients commonly receive statins for the prevention of cardiovascular diseases, and antidepressant drugs for the treatment of depression. It should be noted that long-term polypharmacotherapy may lead to potential drug interactions and disorders of the organs. The aim of the present study was to determine whether, and to what extent, combined treatment with rosuvastatin and antidepressants (amitriptyline or fluoxetine) influences the biochemical markers of liver and kidney function in a rat model. For this purpose, the activity levels of aspartate aminotransferase, alanine aminotransferase (ALT), γ-glutamyltransferase (GGT) and the concentrations of total protein, urea, creatinine and β2-microglobulin were determined. The results of the study indicated that combined treatment with rosuvastatin and the antidepressants amitriptyline and fluoxetine for 14 days altered the activity levels of ALT and GGT, and the concentrations of urea and creatinine in the serum compared with groups of rats receiving rosuvastatin or either antidepressant alone.
2.Determination of Degradation Products of Cyclobenzaprine Hydrochloride, Lidocaine and Piroxicam in a Semi-Topical Formulation: MS-MS Confirmation of Unknown Impurities.
Cioroiu BI1, Grigoriu IC2, Cioroiu ME3, Niculaua M4, Lupuleasa R5, Lazar MI6. J Chromatogr Sci. 2016 Apr 7. pii: bmw009. [Epub ahead of print]
Association of cyclobenzaprine hydrochloride, piroxicam and lidocaine in a topical formulation is one of the newest innovations in the pharmaceutical formulary field. In this study, a reversed-phase liquid chromatographic method was developed for the establishment of the impurities of cyclobenzaprine hydrochloride, lidocaine and piroxicam in the semisolid topical formulation. In this study, we not only determined 2,6-dimethylaniline, 2-pyrydilamine but also specified impurities of cyclobenzaprine hydrochloride (dibenzosuberenone, amitriptyline, carbinole, cyclobenzaprine N-oxide and anthrachinone). The target compounds were determined using a mobile phase that consisted of a mixture of phosphate buffer (0.025 M; pH 6.2)-acetonitrile-methanol (60 : 13 : 27, v/v/v). A minimum of three supplementary possible degradation products were determined. Using mass spectrometry, the unspecified impurities were identified and the use of correlation matrices permitted the association with the possible source compounds.
3.Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism.
O'Neill E1, Kwok B2, Day JS2, Connor TJ2, Harkin A3. Pharmacol Res Perspect. 2016 Mar 8;4(2):e00195. doi: 10.1002/prp2.195. eCollection 2016.
Neuritic degeneration and synaptic loss are features of both neuroinflammation and neurodegenerative disease. The tricyclic antidepressant amitriptyline has neurotrophic and anti-inflammatory properties and acts as a novel agonist of the neurotrophin Trk receptors. Primary cortical neurons were treated with amitriptyline, nortriptyline and NGF and tested for neuronal complexity by Sholl analysis, protein expression by Western immunoblotting, and synapse number by colocalization of pre and postsynaptic makers. Amitriptyline (500 nmol/L) and its active metabolite nortriptyline (50 nmol/L) are found to induce neurite outgrowth in rat primary cortical neurons. Amitriptyline-induced neurite outgrowth is blocked by inhibition of Trk signaling using Trk antagonist K252a (200 nmol/L) but not by the neurotrophin inhibitor Y1036 (40 μmol/L), indicating that amitriptyline binds directly to the Trk receptor to initiate neurite outgrowth. MEK inhibitor PD98059 (10 μmol/L) also blocks amitriptyline-induced neurite outgrowth, implicating activation of the MAPK signaling pathway downstream of Trk receptor activation.
4.Pilot Randomized Controlled Trial of Laparoscopic Cholecystectomy vs Active Nonoperative Therapy for the Treatment of Biliary Dyskinesia.
Richmond BK1, Grodman C2, Walker J2, Dean S2, Tiley EH3, Hamrick RE3, Statler K3, Emmett M2. J Am Coll Surg. 2016 Mar 11. pii: S1072-7515(16)00218-0. doi: 10.1016/j.jamcollsurg.2016.02.022. [Epub ahead of print]
BACKGROUND: Despite widespread adoption by the surgical community, high-quality prospective data supporting the practice of laparoscopic cholecystectomy (LC) for the treatment of biliary dyskinesia (BD) are lacking.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


Nortriptyline Impurity G
(CAS: 16234-88-1)

An impurity of Nortriptyline, which is a non-selective monoamine reuptake inhibitor could be used for the treatment of major depression and childhood nocturnal ...

Clomipramine impurity C
(CAS: 2095-42-3)

CAS 4317-14-0 Amitriptyline-N-Oxide

Amitriptyline-N-Oxide
(CAS: 4317-14-0)

Amitriptyline Related Compound

CAS 549-18-8 Amitriptyline Hydrochloride

Amitriptyline Hydrochloride
(CAS: 549-18-8)

Amitriptyline inhibits serotonin receptor, norepinephrine receptor, 5-HT4, 5-HT2 and sigma 1 receptor with IC50 of 3.45 nM, 13.3 nM, 7.31 nM, 235 nM and 287 nM,...

CAS 549-18-8 Nortriptyline Impurity F

Nortriptyline Impurity F
(CAS: 549-18-8)

An impurity of Nortriptyline, which is a non-selective monoamine reuptake inhibitor could be used for the treatment of major depression and childhood nocturnal ...

CAS 956-82-1 DL-Muscone

DL-Muscone
(CAS: 956-82-1)

Chemical Structure

CAS 50-48-6 Amitriptyline

Quick Inquiry

Verification code

Featured Items